Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- VFS +5.3%, CAL +1.4% (guidance)
Other news:
- ORTX +96.6% (to be acquired by Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS)
- VNET +5.1% (Announces Results of 2023 Extraordinary General Meeting)
- ALXO +4.7% (had approximately $196.5 million of cash cash equivalents and short-term and long-term investments as of September 30 2023)
- OSTK +4.6% (Director disclosed the purchase of 33.000 shares at $14.83 - $15.06 worth more than $493K)
- VCYT +4.3% (presents new data from phase 3 trial for Decipher Prostate Genomic Classifier)
- BB +3.3% (to separate IoT and Cybersecurity units into two independently-operated entities)
- QURE +3.3% (announced a strategic reorganization aimed at reducing operating expenses)
- PFMT +3% (awarded contract by NY state)
- APLS +2.9% (provides an update on the launch of SYFOVRE for geographic atrophy secondary to age-related macular degeneration)
- ASLE +2.4% (updates status of AerAware certification by the FAA)
- HR +2.3% (publishes investor day presentation and provides update on asset sales and new leasing momentum)
- PSNY +2.3% (reports its global deliveries for the third quarter)
- MNOV +2% (receives gene therapy milestone payment)
- KAMN +1.9% (wins US Army contract)
- CSTL +1.7% (DecisionDx-Melanoma outperforms Memorial Sloan Kettering Cancer Center nomogram in predicting sentinel lymph node positivity in patients with cutaneous melanoma)
- NBIX +1.2% (Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints)
Analyst comments:
- UWMC +2.1% (upgraded to Buy from Neutral at BTIG Research)
- PH +1.7% (upgraded to Buy from Neutral at BofA Securities)
- TV +1.7% (upgraded to Buy from Neutral at BofA Securities)
- BECN +1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)